Register or Sign in to Save this opportunity, or Send an Inquiry.
Early Stage, CIS Pharma Develops Cellophil® Antibody Drug Conjugates (ADCs) to Upgrade the Arsenal Against Cancer.
CIS Pharma AG, Switzerland Switzerland flag Switzerland
Abstract ID:
CIS Pharma develops Cellophil® Antibody drug conjugates to conquer the limitations of conventional ADCs by increase of cytotoxic payloads even for strong hydrophobic drugs.
Send an Inquiry
RE:
Participants
You
FEATURED
Last Updated Feb 2019
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
CORPORATION

Opportunity Contact


Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833